Axsome Therapeutics AXSM
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
Axsome Therapeutics (AXSM) Business Model and Operations Summary
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
Key Insights
Axsome Therapeutics (AXSM) Core Market Data and Business Metrics
Latest Closing Price
$111.67Market Cap
$5.41 BillionPrice-Earnings Ratio
-18.64Total Outstanding Shares
48.77 Million SharesTotal Employees
589Dividend
No dividendIPO Date
November 19, 2015SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
One World Trade Center, 22nd Floor, New York, NY, 10007
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $57.84 Million |
| Net Cash Flow From Operating Activities, Continuing | $-128.41 Million |
| Net Cash Flow | $-70.84 Million |
| Net Cash Flow From Investing Activities, Continuing | $-270,000 |
| Net Cash Flow From Financing Activities | $57.84 Million |
| Net Cash Flow From Operating Activities | $-128.41 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income/Loss From Continuing Operations After Tax | $-287.22 Million |
| Net Income/Loss | $-287.22 Million |
| Basic Average Shares | $47.91 Million |
| Net Income/Loss Attributable To Parent | $-287.22 Million |
| Benefits Costs and Expenses | $672.82 Million |
| Interest Expense, Operating | $-21.58 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Other Comprehensive Income/Loss | $0 |
| Comprehensive Income/Loss | $-287.22 Million |
| Comprehensive Income/Loss Attributable To Parent | $-287.22 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Intangible Assets | $46.89 Million |
| Current Liabilities | $230.10 Million |
| Accounts Payable | $72.00 Million |
| Liabilities | $511.48 Million |
| Assets | $568.50 Million |
| Equity | $57.02 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||